Biomarker identification in neurologic diseases

Improving diagnostics and therapeutics

Keith D. Coon, Travis Dunckley, Dietrich A. Stephan

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Identification of biomarkers in neurological disease remains impeded by many obstacles. Among them are the availability of tissue at the site of pathology, poor clinical diagnostics, the complexity of the brain and a general dearth of functional end points and models for validation. However, advances in technology have helped to overcome these challenges. Some of these advances include standardization and increased efficiency in brain banking, novel techniques for brain imaging, improved methods for reducing tissue heterogeneity including laser capture microdissection, high-throughput genomics, new functional validation techniques such as RNA interference, and the development of new animal models of neurologic disease. In order to efficiently handle the wealth of information that will be gleaned from these new technologies, new integrated databasing protocols will be necessary. Access to these databases by researchers and clinicians is critical to the continued progress being made in biomarker identification in neurological disease. These challenges and ways to overcome them are presented here in the context of a disease known to be a robust model for biomarker identification, Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)361-375
Number of pages15
JournalExpert Review of Molecular Diagnostics
Volume4
Issue number3
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Nervous System Diseases
Biomarkers
Laser Capture Microdissection
Technology
Clinical Pathology
Brain
Genomics
RNA Interference
Neuroimaging
Alzheimer Disease
Therapeutics
Animal Models
Research Personnel
Databases

Keywords

  • Alzheimer's disease
  • Biomaker
  • Brain banking
  • Endophenotype
  • Neuroimaging
  • Neuroligic

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Biomarker identification in neurologic diseases : Improving diagnostics and therapeutics. / Coon, Keith D.; Dunckley, Travis; Stephan, Dietrich A.

In: Expert Review of Molecular Diagnostics, Vol. 4, No. 3, 01.05.2004, p. 361-375.

Research output: Contribution to journalReview article

@article{959f7746ffad4490a353aad74f9e6d3c,
title = "Biomarker identification in neurologic diseases: Improving diagnostics and therapeutics",
abstract = "Identification of biomarkers in neurological disease remains impeded by many obstacles. Among them are the availability of tissue at the site of pathology, poor clinical diagnostics, the complexity of the brain and a general dearth of functional end points and models for validation. However, advances in technology have helped to overcome these challenges. Some of these advances include standardization and increased efficiency in brain banking, novel techniques for brain imaging, improved methods for reducing tissue heterogeneity including laser capture microdissection, high-throughput genomics, new functional validation techniques such as RNA interference, and the development of new animal models of neurologic disease. In order to efficiently handle the wealth of information that will be gleaned from these new technologies, new integrated databasing protocols will be necessary. Access to these databases by researchers and clinicians is critical to the continued progress being made in biomarker identification in neurological disease. These challenges and ways to overcome them are presented here in the context of a disease known to be a robust model for biomarker identification, Alzheimer's disease.",
keywords = "Alzheimer's disease, Biomaker, Brain banking, Endophenotype, Neuroimaging, Neuroligic",
author = "Coon, {Keith D.} and Travis Dunckley and Stephan, {Dietrich A.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1586/14737159.4.3.361",
language = "English (US)",
volume = "4",
pages = "361--375",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Biomarker identification in neurologic diseases

T2 - Improving diagnostics and therapeutics

AU - Coon, Keith D.

AU - Dunckley, Travis

AU - Stephan, Dietrich A.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Identification of biomarkers in neurological disease remains impeded by many obstacles. Among them are the availability of tissue at the site of pathology, poor clinical diagnostics, the complexity of the brain and a general dearth of functional end points and models for validation. However, advances in technology have helped to overcome these challenges. Some of these advances include standardization and increased efficiency in brain banking, novel techniques for brain imaging, improved methods for reducing tissue heterogeneity including laser capture microdissection, high-throughput genomics, new functional validation techniques such as RNA interference, and the development of new animal models of neurologic disease. In order to efficiently handle the wealth of information that will be gleaned from these new technologies, new integrated databasing protocols will be necessary. Access to these databases by researchers and clinicians is critical to the continued progress being made in biomarker identification in neurological disease. These challenges and ways to overcome them are presented here in the context of a disease known to be a robust model for biomarker identification, Alzheimer's disease.

AB - Identification of biomarkers in neurological disease remains impeded by many obstacles. Among them are the availability of tissue at the site of pathology, poor clinical diagnostics, the complexity of the brain and a general dearth of functional end points and models for validation. However, advances in technology have helped to overcome these challenges. Some of these advances include standardization and increased efficiency in brain banking, novel techniques for brain imaging, improved methods for reducing tissue heterogeneity including laser capture microdissection, high-throughput genomics, new functional validation techniques such as RNA interference, and the development of new animal models of neurologic disease. In order to efficiently handle the wealth of information that will be gleaned from these new technologies, new integrated databasing protocols will be necessary. Access to these databases by researchers and clinicians is critical to the continued progress being made in biomarker identification in neurological disease. These challenges and ways to overcome them are presented here in the context of a disease known to be a robust model for biomarker identification, Alzheimer's disease.

KW - Alzheimer's disease

KW - Biomaker

KW - Brain banking

KW - Endophenotype

KW - Neuroimaging

KW - Neuroligic

UR - http://www.scopus.com/inward/record.url?scp=2542475991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542475991&partnerID=8YFLogxK

U2 - 10.1586/14737159.4.3.361

DO - 10.1586/14737159.4.3.361

M3 - Review article

VL - 4

SP - 361

EP - 375

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7159

IS - 3

ER -